Ozempic 0.5 mg solution for injection in pre-filled pen
Sponsors
Aarhus University Hospital, Odense University Hospital, Aarhus University Hospital, Bispebjerg Hospital, Steno Diabetes Center Copenhagen, Novo Nordisk A/S
Conditions
"double diabetes"Cardiovascular disorders: Hypertension and ObesityChronic Kidney DiseaseChronic kidney diseaseCraving for and use of chemsex-related drugsDiabetic foot ulcerHIV & ObesityIdiopathic Intracranial Hypertension
Phase 2
The safety and efficacy of acute subcutaneous administration of semaglutide in non-diabetic patients with acute ischemic stroke: a multicentre, phase 2, prospective, randomized, open-label, blinded endpoint trial (ASSET)
RecruitingCTIS2022-501072-25-02
Start: 2023-04-12Target: 380Updated: 2023-06-20
A randomised, controlled, parallel group, open-label trial evaluating the impact of treatment with the GLP-1 analogue semaglutide on weight loss in people living with HIV and obesity (SWIFT Study)
RecruitingCTIS2024-513168-24-00
Start: 2022-06-01Target: 80Updated: 2025-12-19
Efficacy, safety, and pharmacokinetics of NNC0519-0130 once weekly s.c. versus semaglutide 1.0 mg and placebo in people with chronic kidney disease, with or without type 2 diabetes, and with overweight or obesity: a proof-of-concept and dose-finding study
RecruitingCTIS2024-510846-15-00
Start: 2025-04-14Target: 120Updated: 2025-10-30
The SEMAFOOT2 Pilot. Effect of semaglutide on healing of foot ulcers in type 2 diabetes patients. A Pilot study.
Not yet recruitingCTIS2023-504913-65-01
Target: 100Updated: 2025-09-29
An open-label, single-center, non-controlled pilot clinical trial to assess the efficacy of weekly semaglutide in combination with regular counselling sessions to reduce craving and use of chemsex associated drugs (CoSem4Chemsex) study.
Not yet recruitingCTIS2025-524177-16-00
Target: 22Updated: 2026-02-12
Phase 3
A randomised double-blind placebo-controlled clinical study investigating the effects of semaglutide s.c. once-weekly versus placebo on central and peripheral inflammation in participants with Alzheimer’s disease.
CompletedCTIS2023-506825-13-00
Start: 2023-07-25End: 2025-06-26Target: 13Updated: 2025-02-17
Multifactorial intervention to reduce cardiovascular disease in type 1 diabetes
RecruitingCTIS2023-505794-32-04
Start: 2024-07-05Target: 2000Updated: 2025-11-05
TOLEDDO: Effect of weekly GLP1 agonist treatment in "double diabetes": a randomized, open-label study
RecruitingCTIS2024-514906-30-00
Start: 2024-10-14Target: 76Updated: 2025-12-09
Semaglutide for people with obesity and resistant hypertension (SUPPORT): a pilot, randomized, parallel-group, integrated, multicentre clinical trial.
RecruitingCTIS2024-513958-29-00
Start: 2025-04-24Target: 50Updated: 2025-11-10
Phase 4
Screening and intervention for subclinical coronary artery disease in patients with type 2 diabetes:
THE STENO INTEN-CT STUDY
RecruitingCTIS2022-500143-21-01
Start: 2023-01-12Target: 7300Updated: 2024-09-20
Glucagone Like Peptide-1 Receptor (GLP-1R) Analogue Assisted Rapid Weight Loss Program as treatment of Idiopathic Intracranial Hypertension
CompletedCTIS2024-517120-19-02
Start: 2022-09-02End: 2025-10-28Target: 50Updated: 2025-06-04
Open-label, double-arm, controlled, randomized, multicentre clinical trial to evaluate the impact of pharmacogenetic-guided treatment in patients with insufficiently controlled type 2 diabetes
Active, not recruitingCTIS2025-520686-46-00
Start: 2025-05-15Target: 504Updated: 2025-09-15
Semaglutide and Finerenone for Kidney and Vascular Protection in CKD
RecruitingCTIS2025-522503-18-00
Start: 2025-10-27Target: 160Updated: 2025-09-09
Healing Diabetic Foot Ulcers with Semaglutide
Not yet recruitingCTIS2025-524738-24-00
Target: 70Updated: 2026-03-30